Market Outlook—Convincing Hesitant Investors for IPOs versus Other Capital Alternatives

With biotechnology stock index values dipping 20% across the past year and IPO volume down more than 70%, many companies are forced to raise capital outside the traditional stock offering path, or indefinitely delay acting while tightening cash flows.  A few outlier IPOs buck this trend.  This panel will discuss prioritizing fundraising options including debt financing, SPAC deals, reverse mergers, and royalty arrangements amid the current higher-interest rate macroeconomic environment, as well as which IPOs and follow-on offerings ought to be able to outperform.